Current Setup & Catalysts
Current Setup & Catalysts — Molina Healthcare (MOH)
The setup in one paragraph
Molina sits 38 days from the most important earnings print since the 2025 dislocation began: Q2 2026 (release after the close on Wednesday, July 22, 2026, call July 23) is the second consecutive print under the new $5.00 floor guide and the first chance for the cycle-inflection narrative — already half-priced by a +37% three-month rally to $200 — to be re-confirmed or reversed. The stock is back above the $184 average sell-side target, a golden cross printed June 2, 2026, the short book has covered 42% from its November 2025 peak, and management's May 8, 2026 Investor Day reaffirmed a $25 adjusted-EPS target by 2029. None of that resolves the underwriting question. The decisive signal is favorable prior-year reserve development (PYD) in Q2 and Q3 alongside Medicaid MCR moving below 91.5% — the bridge between the 5-to-10-year thesis (whether Medicaid spread economics are intact) and what the market actually learns this calendar year.
Last Price ($, Jun 12)
3-Month Return
1-Year Return
Avg Analyst Target ($)
FY26 Adj EPS Guide (≥)
FY26 Adj EPS Consensus
FY29 Mgmt Adj EPS Target
Days to Q2 2026 print
Recent setup read: Mixed, leaning constructive. The Q1 2026 print broke the streak of misses, the Investor Day re-anchored the 2029 number, and the short book has materially de-risked. But three of the last four quarterly prints were down 17–25% on the day, the stock has rallied above the average analyst target, and the cycle inflection is one data point old. The setup is not yet resolved — and the next two prints decide whether the inflection holds.
Where we sit vs the Street — the variant view, up front
The honest variant call. We sit modestly above consensus on FY26 ($6.00 vs $5.23, +15%) because Q1's $2.35 implies cadence that is far from the $5.00 floor — but we are below management's $25 FY29 target ($21 vs $25, -16%) because OBBBA enrollment erosion, ACA subsidy expiry, and competitive UNH C&S intensity all bite into the joint-probability of all four pillars holding. The honest read at $200 is symmetric risk-reward — a $50–65 move either way depending on Q2/Q3 PYD and Medicaid MCR resolution. This is not a high-conviction long at spot; it is an asymmetric option whose first cash-out event is 38 days away.
What changed in the last 3–6 months — the market's recent education
The narrative arc. In November 2025 the market was pricing structural margin destruction (8.2% short interest at the peak, stock at $122 lows). By June 2026 it is paying for a cyclical inflection (4.93% short, stock $200, sell-side targets being raised) but has not yet underwritten the FY27 recovery curve — every published target except Mizuho still trades below the bull's $265. The market has moved from "structural" to "uncertain"; it has not moved to "cyclical."
How the stock has actually moved on prints — the base rate
Base-rate read. The post-July-2025 regime has averaged a ~17.5% absolute one-day move per print — roughly 9× the pre-shock norm. The skew was uniformly to the downside through Feb 2026; Q1 2026 was the first reversal. Q2 prints into an asymmetric setup: the consensus number is anchored on a low FY26 guide, but the stock has already rallied +37% on Q1 alone. A modest beat may already be priced; a clean miss or weak PYD will move the stock 12–20%. Magnitude estimates downstream rest on this base rate, not on a generic "earnings can move ±X%" intuition.
The live debate — what the market is watching now
The live debate is not dispersed across nine items. It is concentrated on the first two — Medicaid MCR sequencing and PYD adequacy — both of which print in Q2 (July 22) and Q3 (~Oct 22). Items 3–9 update around those data points; they do not preempt them. A PM should care about Q2 and Q3 first; everything else is detail.
Ranked catalyst timeline — the single most important table on this page
Ranked by decision value to an institutional investor, not by date. The variant magnitudes for High-impact rows are sized using the post-July-2025 base-rate window (avg ~17.5% absolute move per print). The skew column reads outcome asymmetry; confidence reads date and evidence quality.
Read the table this way. Rows 1 and 2 (Q2 and Q3 prints) carry almost all of the decision value in the next six months. Rows 3–6 update around them — they refine the thesis but do not resolve it. Row 7 (Q4 26 print) sits outside the 6-month window but is the largest single catalyst in the next 12 months and is flagged here so the next 90 days are not optimized at the cost of the print that actually re-rates the multiple. Rows 8–10 are noise or context for this six-month frame.
Impact & decision view — resolution vs information
The next 90 days — what a PM should watch
The visible window between today (June 14, 2026) and Sept 14, 2026 is dominated by a single hard date: Q2 2026 earnings on July 22. Everything else is preview, drift, or process.
The honest 90-day read. Outside of Q2 on July 22, the next 90 days are mostly observation, not action. A PM should not size into this name expecting a near-term catalyst other than Q2 — and Q2 alone justifies a watchlist position rather than a sizing-up decision. The cycle-resolution prints (Q3 in October, Q4 in February 2027) are still ahead and decision-decisive. The right posture is watchlist build with a Q2 trigger.
What would change the view
These are the two-to-three observable signals over the next six months that would force a thesis update. They sit underneath every row of the catalyst timeline and they tie back to the Long-Term Thesis pillars, the Bull/Bear cases, and the Forensic file.
The single most decision-relevant signal in the next 90 days is the PYD line in Q2's medical-claims-payable rollforward. It is one line. It validates or refutes both the cycle-inflection narrative AND the Hindlemann securities theory at the same time, and it determines whether the +37% rally compounds or unwinds. A PM should know exactly where to find this line in the 10-Q (note on Medical Claims and Benefits Payable, the prior-year reserve development column) before market open on July 23.
Coverage limits and source notes
- All consensus figures referenced are post Q1 26 print (Apr 22, 2026); Zacks 2026 EPS consensus $5.23 with 5 upward revisions / 0 down in 60 days.
- Sell-side targets cited: Mizuho $215 (Jun 8), Morgan Stanley $167 (Jun 4), UBS $202 (May 22); average $184.25 across the visible set of 18 analysts (stockanalysis.com).
- Verified hard dates: Q2 2026 earnings — Wednesday, July 22, 2026 after close (Molina IR Jun 2, 2026 release; conference call Thu Jul 23 at 8:00 AM ET); Illinois Medicaid contract go-live — January 1, 2027 (Molina 8-K Jun 10, 2026); OBBBA Medicaid work-requirement effective date — January 1, 2027 (statute); Investor Day — May 8, 2026 (executed; 2029 $25 adj EPS target re-affirmed).
- Soft windows flagged honestly: Florida CMS Kids start date ("TBD" per Nov 14, 2025 8-K; business agent cites Q4 2026 expectation); Q3 2026 print (~Oct 22, 2026 based on historical cadence); state CY2027 rate-notice publications (state-by-state).
- Magnitude sizing rests on the post-July-2025 base rate (~17.5% average absolute one-day move on prints, n=4) and the bull/bear price targets ($265 / $120, $200 spot).
- This page does not re-litigate the Bull/Bear final verdict (that is the Bull & Bear tabs) and does not issue a position recommendation. It is the bridge between the durable 5-to-10-year thesis and the near-term evidence path that will update it.